Healthcare / Medical DevicesSwiss
$19.30
-2.04 (-9.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-2.9M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$761M
P/E
386.0x
↑EV/EBITDA
84.3x
↑ROE
3.0%
↑Gross Margin
88.6%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+101.0%
FCF CAGR
—
FCF margin
-2.0%
FCF / Net income
-1.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $146.1M · net income $2.6M · FCF $-2.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $146.1M | $146.1M | $85.2M | $33.6M | $18.0M |
| Net Income | $2.6M | $2.6M | $-4.8M | $-10.2M | $-14.6M |
| EBITDA | $8.8M | $8.8M | $-633000.00 | $-6.8M | $-13.0M |
| EPS | — | — | -0.13 | -0.38 | -0.43 |
| Gross Margin | 88.6% | 88.6% | 82.1% | 71.3% | 59.9% |
| Operating Margin | 6.1% | 6.1% | -6.6% | -28.7% | -74.8% |
| Net Margin | 1.7% | 1.7% | -5.7% | -30.3% | -81.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 |
| Current Ratio | 1.96 | 1.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.9M | $-2.9M | $2.3M | $-9.2M | $-7.7M |
| Returns | |||||
| ROE | 3.0% | 3.0% | -7.5% | -17.9% | -21.2% |
| Valuation | |||||
| P/E | 386.00 | 386.00 | — | — | — |
| EV/EBITDA | 84.31 | 84.31 | — | — | — |
| P/B | 8.95 | 8.95 | 12.41 | 2.87 | 0.79 |
| Growth & Yield | |||||
| Revenue Growth | 71.5% | 71.5% | 153.7% | 86.6% | — |
| EPS Growth | — | — | 65.8% | 11.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-22.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.13 → n/d
Residual
-22.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.